Highly efficient soluble expression and purification of recombinant human basic fibroblast growth factor (hbFGF) by fusion with a new collagen-like protein (Scl2) in Escherichia coli

Human basic fibroblast growth factor (hbFGF) is involved in a wide range of biological activities that affect the growth, differentiation, and migration. Due to its wound healing effects and therapy, hbFGF has the potential as therapeutic agent. Therefore, large-scale production of biologically acti...

Full description

Saved in:
Bibliographic Details
Published inPreparative biochemistry & biotechnology Vol. 50; no. 6; pp. 598 - 606
Main Authors Rahman, Inamur, Fang, Lina, Wei, Zhang, Zheng, Xiaodong, Jiazhang, Lian, Huang, Lei, Xu, Zhinan
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 02.07.2020
Taylor & Francis Ltd
Subjects
Online AccessGet full text
ISSN1082-6068
1532-2297
1532-2297
DOI10.1080/10826068.2020.1721533

Cover

Loading…
Abstract Human basic fibroblast growth factor (hbFGF) is involved in a wide range of biological activities that affect the growth, differentiation, and migration. Due to its wound healing effects and therapy, hbFGF has the potential as therapeutic agent. Therefore, large-scale production of biologically active recombinant hbFGF with low cost is highly desirable. However, the complex structure of hbFGF hinders its high-level expression as the soluble and functional form. In the present study, an efficient, cost-effective, and scalable method for producing recombinant hbFGF was developed. The modified collagen-like protein (Scl2-M) from Streptococcus pyogenes was used as the fusion tag for producing recombinant hbFGF for the first time. After optimization, the expression level of Scl2-M-hbFGF reached approximately 0.85 g/L in the shake flask and 7.7 g/L in a high cell-density fermenter using glycerol as a carbon source. Then, the recombinant Scl2-M-hbFGF was readily purified using one-step acid precipitation and the purified Scl2-M-hbFGF was digested with enterokinase. The digested mixture was further subject to ion-exchange chromatography, and the final high-purity (96%) hbFGF product was prepared by freeze-drying. The recovery rate of the whole purification process attained 55.0%. In addition, the biological activity of recombinant hbFGF was confirmed by using L929 and BALB/c3T3 fibroblasts. Overall, this method has the potential for large scale production of recombinant hbFGF.
AbstractList Human basic fibroblast growth factor (hbFGF) is involved in a wide range of biological activities that affect the growth, differentiation, and migration. Due to its wound healing effects and therapy, hbFGF has the potential as therapeutic agent. Therefore, large-scale production of biologically active recombinant hbFGF with low cost is highly desirable. However, the complex structure of hbFGF hinders its high-level expression as the soluble and functional form. In the present study, an efficient, cost-effective, and scalable method for producing recombinant hbFGF was developed. The modified collagen-like protein (Scl2-M) from was used as the fusion tag for producing recombinant hbFGF for the first time. After optimization, the expression level of Scl2-M-hbFGF reached approximately 0.85 g/L in the shake flask and 7.7 g/L in a high cell-density fermenter using glycerol as a carbon source. Then, the recombinant Scl2-M-hbFGF was readily purified using one-step acid precipitation and the purified Scl2-M-hbFGF was digested with enterokinase. The digested mixture was further subject to ion-exchange chromatography, and the final high-purity (96%) hbFGF product was prepared by freeze-drying. The recovery rate of the whole purification process attained 55.0%. In addition, the biological activity of recombinant hbFGF was confirmed by using L929 and BALB/c3T3 fibroblasts. Overall, this method has the potential for large scale production of recombinant hbFGF.
Human basic fibroblast growth factor (hbFGF) is involved in a wide range of biological activities that affect the growth, differentiation, and migration. Due to its wound healing effects and therapy, hbFGF has the potential as therapeutic agent. Therefore, large-scale production of biologically active recombinant hbFGF with low cost is highly desirable. However, the complex structure of hbFGF hinders its high-level expression as the soluble and functional form. In the present study, an efficient, cost-effective, and scalable method for producing recombinant hbFGF was developed. The modified collagen-like protein (Scl2-M) from Streptococcus pyogenes was used as the fusion tag for producing recombinant hbFGF for the first time. After optimization, the expression level of Scl2-M-hbFGF reached approximately 0.85 g/L in the shake flask and 7.7 g/L in a high cell-density fermenter using glycerol as a carbon source. Then, the recombinant Scl2-M-hbFGF was readily purified using one-step acid precipitation and the purified Scl2-M-hbFGF was digested with enterokinase. The digested mixture was further subject to ion-exchange chromatography, and the final high-purity (96%) hbFGF product was prepared by freeze-drying. The recovery rate of the whole purification process attained 55.0%. In addition, the biological activity of recombinant hbFGF was confirmed by using L929 and BALB/c3T3 fibroblasts. Overall, this method has the potential for large scale production of recombinant hbFGF.
Human basic fibroblast growth factor (hbFGF) is involved in a wide range of biological activities that affect the growth, differentiation, and migration. Due to its wound healing effects and therapy, hbFGF has the potential as therapeutic agent. Therefore, large-scale production of biologically active recombinant hbFGF with low cost is highly desirable. However, the complex structure of hbFGF hinders its high-level expression as the soluble and functional form. In the present study, an efficient, cost-effective, and scalable method for producing recombinant hbFGF was developed. The modified collagen-like protein (Scl2-M) from Streptococcus pyogenes was used as the fusion tag for producing recombinant hbFGF for the first time. After optimization, the expression level of Scl2-M-hbFGF reached approximately 0.85 g/L in the shake flask and 7.7 g/L in a high cell-density fermenter using glycerol as a carbon source. Then, the recombinant Scl2-M-hbFGF was readily purified using one-step acid precipitation and the purified Scl2-M-hbFGF was digested with enterokinase. The digested mixture was further subject to ion-exchange chromatography, and the final high-purity (96%) hbFGF product was prepared by freeze-drying. The recovery rate of the whole purification process attained 55.0%. In addition, the biological activity of recombinant hbFGF was confirmed by using L929 and BALB/c3T3 fibroblasts. Overall, this method has the potential for large scale production of recombinant hbFGF.Human basic fibroblast growth factor (hbFGF) is involved in a wide range of biological activities that affect the growth, differentiation, and migration. Due to its wound healing effects and therapy, hbFGF has the potential as therapeutic agent. Therefore, large-scale production of biologically active recombinant hbFGF with low cost is highly desirable. However, the complex structure of hbFGF hinders its high-level expression as the soluble and functional form. In the present study, an efficient, cost-effective, and scalable method for producing recombinant hbFGF was developed. The modified collagen-like protein (Scl2-M) from Streptococcus pyogenes was used as the fusion tag for producing recombinant hbFGF for the first time. After optimization, the expression level of Scl2-M-hbFGF reached approximately 0.85 g/L in the shake flask and 7.7 g/L in a high cell-density fermenter using glycerol as a carbon source. Then, the recombinant Scl2-M-hbFGF was readily purified using one-step acid precipitation and the purified Scl2-M-hbFGF was digested with enterokinase. The digested mixture was further subject to ion-exchange chromatography, and the final high-purity (96%) hbFGF product was prepared by freeze-drying. The recovery rate of the whole purification process attained 55.0%. In addition, the biological activity of recombinant hbFGF was confirmed by using L929 and BALB/c3T3 fibroblasts. Overall, this method has the potential for large scale production of recombinant hbFGF.
Author Jiazhang, Lian
Huang, Lei
Fang, Lina
Zheng, Xiaodong
Rahman, Inamur
Xu, Zhinan
Wei, Zhang
Author_xml – sequence: 1
  givenname: Inamur
  surname: Rahman
  fullname: Rahman, Inamur
  organization: Center for Synthetic Biology, College of Chemical and Biological Engineering, Zhejiang University
– sequence: 2
  givenname: Lina
  surname: Fang
  fullname: Fang, Lina
  organization: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd
– sequence: 3
  givenname: Zhang
  surname: Wei
  fullname: Wei, Zhang
  organization: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd
– sequence: 4
  givenname: Xiaodong
  surname: Zheng
  fullname: Zheng, Xiaodong
  organization: Fuli Institute of Food Science, College of Biosystems Engineering and Food Science, Zhejiang University
– sequence: 5
  givenname: Lian
  surname: Jiazhang
  fullname: Jiazhang, Lian
  email: jzlian@zju.edu.cn
  organization: Center for Synthetic Biology, College of Chemical and Biological Engineering, Zhejiang University
– sequence: 6
  givenname: Lei
  surname: Huang
  fullname: Huang, Lei
  organization: Center for Synthetic Biology, College of Chemical and Biological Engineering, Zhejiang University
– sequence: 7
  givenname: Zhinan
  surname: Xu
  fullname: Xu, Zhinan
  email: znxu@zju.edu.cn
  organization: Center for Synthetic Biology, College of Chemical and Biological Engineering, Zhejiang University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32027221$$D View this record in MEDLINE/PubMed
BookMark eNqFks1u3CAQx60qVfPRPkIrpF42B6eAje1VL6mibFIpUg9tzwjwsCbFsAWs7b5Yn684u3vJobkwaPj9Z4aZOS9OnHdQFO8JviK4w5_yQRvcdFcU0-xqKWFV9ao4y4aWlC7bk3zPTDlDp8V5jI8Yk2VLujfFaZVFLaXkrPh7b9aD3SHQ2igDLqHo7SQtIPizCRCj8Q4J16PNFExGRJodXqMAyo_SOJElwzQKh6SIRiFtZPDSipjQOvhtGpAWKvmAFoNc3a0ukdwhPT2F3Zr8KpCDLVLeWrEGV1rzC9Am-ATGocV3ZeklyrfbqAYIRg1GzKx5W7zWwkZ4d7AXxc_V7Y-b-_Lh293Xmy8Ppappm0pFmmVFmcINI30nABrdzH1iHWhZdR1TXV0ziomssaoxlXVuo8TQ9IKQnsnqoljs4-aSfk8QEx9NVJCLdeCnyCnL8WrasPZltMqJGG4rltGPz9BHPwWXP8JproCSpiHLTH04UJMcoeebYEYRdvw4vAx83gMq-BgDaK5MehpQCsJYTjCfV4UfV4XPq8IPq5LV7Jn6mOAl3fVeZ5z2YRRbH2zPk9hZH3QQTpnIq_-H-Aeg4dSS
CitedBy_id crossref_primary_10_3389_fphar_2023_1279516
crossref_primary_10_1007_s00425_024_04456_5
crossref_primary_10_1039_D2MH00652A
Cites_doi 10.1016/0167-4838(95)00060-8
10.1007/s12010-013-0140-3
10.3390/ijms14023556
10.1074/jbc.M201163200
10.1023/A:1018325604264
10.1186/1475-2859-11-146
10.1016/j.pep.2005.06.012
10.1007/s00253-008-1774-x
10.1007/s00253-012-4592-0
10.1016/S1046-5928(02)00601-0
10.4061/2011/973741
10.5812/ircmj.21615
10.1016/0300-9084(96)88120-X
10.1023/B:WIBI.0000021750.22050.55
10.1016/j.pep.2008.02.009
10.1016/S0021-9258(18)37592-6
10.2174/0929866023409011
10.1007/s10529-006-9018-6
10.1016/j.pep.2005.03.016
10.1111/j.1524-475X.2008.00410.x
10.1210/er.18.1.26
10.1007/BF01288365
10.1134/S000629790902014X
10.3109/08977198909069078
10.1006/prep.1997.0834
10.1038/srep33948
10.1093/cvr/cvu239
10.1007/s00253-013-5475-8
10.1006/prep.1997.0759
10.1371/journal.pone.0117448
10.1007/s11274-014-1649-5
10.1159/000441453
10.1016/S0378-4347(99)00394-1
ContentType Journal Article
Copyright 2020 Taylor & Francis Group, LLC 2020
2020 Taylor & Francis Group, LLC
Copyright_xml – notice: 2020 Taylor & Francis Group, LLC 2020
– notice: 2020 Taylor & Francis Group, LLC
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QO
7QR
7T7
7TK
7TM
8FD
C1K
FR3
M7N
P64
7X8
7S9
L.6
DOI 10.1080/10826068.2020.1721533
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Chemoreception Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Nucleic Acids Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Biotechnology Research Abstracts
Technology Research Database
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Nucleic Acids Abstracts
Chemoreception Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList MEDLINE

Biotechnology Research Abstracts
AGRICOLA
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1532-2297
EndPage 606
ExternalDocumentID 32027221
10_1080_10826068_2020_1721533
1721533
Genre Article
Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 21576232, 21606205, and 21808199
– fundername: Natural Science Foundation of Zhejiang Province
  grantid: LY18B060002
– fundername: National Key Research and Development Program of China
  grantid: 2018YFC1603900-2
GroupedDBID ---
-~X
.7F
.QJ
0BK
0R~
123
29O
30N
36B
4.4
53G
5VS
AAENE
AAHBH
AAJMT
AALDU
AAMIU
AAPUL
AAQRR
ABCCY
ABFIM
ABHAV
ABJNI
ABLIJ
ABPAQ
ABPEM
ABTAI
ABXUL
ABXYU
ACGEJ
ACGFS
ACIWK
ACPRK
ACTIO
ADCVX
ADGTB
ADXPE
AEISY
AENEX
AEOZL
AEPSL
AEYOC
AFKVX
AFRAH
AGDLA
AGMYJ
AHDZW
AIJEM
AJWEG
AKBVH
AKOOK
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AQRUH
AVBZW
AWYRJ
BLEHA
CCCUG
CE4
CS3
DGEBU
DKSSO
DU5
EBS
ECGQY
E~A
E~B
F5P
GTTXZ
H13
HF~
HZ~
H~P
IPNFZ
J.P
KYCEM
LJTGL
M4Z
NA5
NW0
O9-
PQQKQ
RIG
RNANH
ROSJB
RTWRZ
S-T
SNACF
TBQAZ
TCY
TDBHL
TFL
TFT
TFW
TTHFI
TUROJ
TWF
UT5
UU3
ZGOLN
~S~
AAGDL
AAHIA
AAYXX
ADYSH
AFRVT
AIYEW
AMPGV
CITATION
.GJ
07J
1TA
AAAJW
AAPPP
ABKVM
ABZMO
ACMLV
ACYAP
ADBHG
ADOGB
AEUXM
AFOFI
AFWJF
AGGGY
AOWVY
AWFQP
BDVFT
BKMSO
C5E
CAG
CGR
COF
CTOBV
CUY
CVF
CXCUG
C~V
ECM
EIF
EJD
HJQDS
LZ8
NPM
NUSFT
OCADI
OEUFU
TASJS
TAV
TCCYZ
TFMCV
UA2
~KM
7QL
7QO
7QR
7T7
7TK
7TM
8FD
C1K
FR3
M7N
P64
7X8
7S9
L.6
ID FETCH-LOGICAL-c427t-c169325c0651d8aee6f6153358efb3885c8445201b40c402b4215b0e6da11d5b3
ISSN 1082-6068
1532-2297
IngestDate Wed Jul 02 04:41:11 EDT 2025
Fri Jul 11 00:27:16 EDT 2025
Wed Aug 13 11:15:38 EDT 2025
Mon Jul 21 06:02:02 EDT 2025
Thu Apr 24 22:57:54 EDT 2025
Tue Jul 01 01:13:24 EDT 2025
Wed Dec 25 09:07:42 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords fibroblast growth factor-2
Bacterial collagen-like protein
fusion expression
Escherichia coli
pH change-dependent acid precipitation
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c427t-c169325c0651d8aee6f6153358efb3885c8445201b40c402b4215b0e6da11d5b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 32027221
PQID 2421216619
PQPubID 196140
PageCount 9
ParticipantIDs informaworld_taylorfrancis_310_1080_10826068_2020_1721533
proquest_miscellaneous_2561542657
proquest_journals_2421216619
proquest_miscellaneous_2352050735
crossref_primary_10_1080_10826068_2020_1721533
crossref_citationtrail_10_1080_10826068_2020_1721533
pubmed_primary_32027221
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-07-02
PublicationDateYYYYMMDD 2020-07-02
PublicationDate_xml – month: 07
  year: 2020
  text: 2020-07-02
  day: 02
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Philadelphia
PublicationTitle Preparative biochemistry & biotechnology
PublicationTitleAlternate Prep Biochem Biotechnol
PublicationYear 2020
Publisher Taylor & Francis
Taylor & Francis Ltd
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Ltd
References Squires C. H. (CIT0024) 1988; 263
CIT0030
Sekiguchi H. (CIT0009) 2018; 2018
CIT0010
CIT0032
CIT0012
CIT0034
CIT0011
CIT0033
CIT0014
CIT0013
Jia X. (CIT0031) 2015; 10
CIT0035
CIT0015
CIT0018
CIT0017
CIT0019
CIT0021
CIT0020
CIT0001
CIT0023
CIT0022
CIT0003
Broedel S. (CIT0016) 2001; 2
CIT0025
CIT0002
CIT0005
CIT0027
CIT0004
CIT0026
CIT0007
CIT0029
CIT0006
CIT0028
CIT0008
References_xml – ident: CIT0028
  doi: 10.1016/0167-4838(95)00060-8
– ident: CIT0023
  doi: 10.1007/s12010-013-0140-3
– ident: CIT0007
  doi: 10.3390/ijms14023556
– ident: CIT0030
  doi: 10.1074/jbc.M201163200
– ident: CIT0006
  doi: 10.1023/A:1018325604264
– ident: CIT0012
  doi: 10.1186/1475-2859-11-146
– ident: CIT0026
  doi: 10.1016/j.pep.2005.06.012
– ident: CIT0015
  doi: 10.1007/s00253-008-1774-x
– ident: CIT0022
  doi: 10.1007/s00253-012-4592-0
– ident: CIT0008
  doi: 10.1016/S1046-5928(02)00601-0
– ident: CIT0034
  doi: 10.4061/2011/973741
– ident: CIT0017
  doi: 10.5812/ircmj.21615
– ident: CIT0011
  doi: 10.1016/0300-9084(96)88120-X
– ident: CIT0019
  doi: 10.1023/B:WIBI.0000021750.22050.55
– ident: CIT0020
  doi: 10.1016/j.pep.2008.02.009
– volume: 263
  start-page: 16297
  year: 1988
  ident: CIT0024
  publication-title: J. Biol. Chem
  doi: 10.1016/S0021-9258(18)37592-6
– ident: CIT0014
  doi: 10.2174/0929866023409011
– volume: 2
  start-page: 1
  year: 2001
  ident: CIT0016
  publication-title: Athena Enzyme Syst. Tech. Bull
– ident: CIT0021
  doi: 10.1007/s10529-006-9018-6
– ident: CIT0010
  doi: 10.1016/j.pep.2005.03.016
– ident: CIT0003
  doi: 10.1111/j.1524-475X.2008.00410.x
– ident: CIT0005
  doi: 10.1210/er.18.1.26
– ident: CIT0018
  doi: 10.1007/BF01288365
– ident: CIT0001
  doi: 10.1134/S000629790902014X
– ident: CIT0002
  doi: 10.3109/08977198909069078
– ident: CIT0027
  doi: 10.1006/prep.1997.0834
– ident: CIT0033
  doi: 10.1038/srep33948
– ident: CIT0004
  doi: 10.1093/cvr/cvu239
– ident: CIT0013
  doi: 10.1007/s00253-013-5475-8
– ident: CIT0025
  doi: 10.1006/prep.1997.0759
– volume: 10
  start-page: e0117448
  year: 2015
  ident: CIT0031
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0117448
– ident: CIT0029
  doi: 10.1007/s11274-014-1649-5
– ident: CIT0032
  doi: 10.1159/000441453
– volume: 2018
  start-page: 1
  year: 2018
  ident: CIT0009
  publication-title: BioMed Res. Int
– ident: CIT0035
  doi: 10.1016/S0378-4347(99)00394-1
SSID ssj0019718
Score 2.1995218
Snippet Human basic fibroblast growth factor (hbFGF) is involved in a wide range of biological activities that affect the growth, differentiation, and migration. Due...
SourceID proquest
pubmed
crossref
informaworld
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 598
SubjectTerms Amino Acid Sequence
Animals
Bacterial collagen-like protein
Bacterial Proteins - genetics
Bacterial Proteins - metabolism
BALB 3T3 Cells
bioactive properties
Biological activity
biotechnology
carbon
Carbon sources
Cell density
Cell Proliferation - drug effects
Chemical compounds
Chromatography, Ion Exchange
Cloning, Molecular - methods
Collagen
Collagen - genetics
Collagen - metabolism
cost effectiveness
culture flasks
E coli
enteropeptidase
Escherichia coli
Escherichia coli - genetics
Escherichia coli - metabolism
fermenters
Fibroblast growth factor 2
Fibroblast Growth Factor 2 - genetics
Fibroblast Growth Factor 2 - metabolism
Fibroblasts
Fibroblasts - drug effects
Fibroblasts - metabolism
Freeze drying
fusion expression
Glycerol
Growth factors
Humans
Ion exchange
Ion-exchange chromatography
Mice
Optimization
pH change-dependent acid precipitation
Pharmacology
Production methods
Proteins
Purification
purification methods
Recombinant Fusion Proteins - isolation & purification
Recombinant Fusion Proteins - metabolism
Recombinant Fusion Proteins - pharmacology
Recombinant Proteins - genetics
Recombinant Proteins - metabolism
Streptococcus pyogenes
Streptococcus pyogenes - metabolism
therapeutics
Wound healing
Title Highly efficient soluble expression and purification of recombinant human basic fibroblast growth factor (hbFGF) by fusion with a new collagen-like protein (Scl2) in Escherichia coli
URI https://www.tandfonline.com/doi/abs/10.1080/10826068.2020.1721533
https://www.ncbi.nlm.nih.gov/pubmed/32027221
https://www.proquest.com/docview/2421216619
https://www.proquest.com/docview/2352050735
https://www.proquest.com/docview/2561542657
Volume 50
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFLbKEBI3iH8KAxmJi01VRuLYaXKJUMtAoyBopd5FseusEV1bdYlEeTAehCfiHNtNU22wwU2aOnaS9nxxznd8fgh5pdQkC8JAerio5fGJ0F7GtPKkxlJIKtHdDKORPw6i4xH_MBbjVutXw2upKuWR-nFpXMn_SBXaQK4YJfsPkq1PCg2wD_KFLUgYtteSMTppzNbok1GYuMYOXg5DofR3599qXY2X1Qo9gmrtEFnwmTQ-MK5IH7zMCtXJgTsvJOjTZecU6Hk5deV4UA2dyv67PtoQQF_NK3NqGxeHRck7Bk5wn96s-IahVwssoonDvqoZw1HwrXeOACnQuRr7F029-PNK10nIZYFVvGwZOoNMaCgvrAB8yabOePt-np1VtY9x3xnAgWRXi-26k3FaMNbxralc257jIgNu7g44AwiwXTSusp05m3mMWTffzaRus9k68Ead5ZFIYi_ym3O1sOWv3WvfHbvwRrEumPABxC9CX0AGjUCbhc3fsZvBe_Ap7Y9OTtJhbzy8QW4yoC5YVSP0B_XKVtI1Nuf6pjdRZbH_-tKL7OhLO9l0_8yJjG40vEvuOFJD31iE3iMtPb9Pbtkyp-sH5KfFKa1xSh1O6RanFHBKmzili5w2cEoNTqnBKd3ilFqcUotTemBQekjlmlqMUsQozShglO5glDqM0gNE6CGFvQY-sW_xkIz6veHbY8_VC_EUZ93SU5hYiAkFWnUwiTOto9zQGRHrXIZxLFTMuQCNV3JfcZ9JDv-w9HUE01UwETJ8RPbmi7l-QqgfZL7OQNvNE855dyJ14usgDxIFIpU8ahO-kUqqXDJ9rOkySwOXc3cjzBSFmTphtslRPWxps8lcNSBpijwtjRkvtzV30vCKsfsbfKRu0jpPjQdIAEp50iYv68PwSOM6YTbXiwr6ACnzgSeG4i99gHcJ0O5Ft00eW-zVvyhEgypjwdNrjH5Gbm-f6X2yV64q_RzU_FK-MM_Nb5Sk-yg
linkProvider Taylor & Francis
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwELWgCMGFb-hCgUHi0B6yihM7H0eEuizQ7oVW6i2KHbuNGpJqm6gsP4zfx4yTrFqk0kNPiRI7ieNn-439PMPYR62LnIdcebSo5YlCGi8PjPaUoVBIOjVxTruR9xfR_FB8O5JHl_bCkKySbGjbO4pwfTU1bpqMHiVxeERS7EekzArwEhoxSFrusnsyjWKKYhD6i_VKQhrzfjscMknKM-7iue4xV8anK95Lr-egbiyaPWZ6LEUvQTmddq2a6t__OHi8XTGfsEcDVYVPPbaesjumfsbu98ErV8_ZH5KIVCswzgkFjl1AMFaVAfNrUNfWgC-Hs25JeiQHAWgskA3-UzkFDrgQgYBDaanBouXeKGTzLRwvm4v2BPpgQLB9omZfZjugVmA791iaPYYc0CQAB2RsBV5VnhpwbifKGrZ_6CrYATzbPSdYliTpprTlC3Y42z34PPeGKBCeFkHceprcxQRSI1fiRZIbE1lHUmVirAqTROpECIk8RglfozWsBP4n5ZsIQcgLqcKXbKNuarPJwOe5b3LkMDYVQsSFMqlvuOWpRhtDiWjCxFj3mR5cpFOkjirjgyfVsUoyqpJsqJIJm66znfU-Qm7KkF4GVta6yRnbR1LJwhvybo0ozIbu5jxz6_ocqVY6YR_Wt7GjoNWfvDZNh2mQavvI_kP5nzTIpiVyNhlP2Kse4esShTRNFgT89S0-_j17MD_Y38v2vi6-v2EP6ZaTPgdbbKNdduYtErxWvXMt-C_lO0El
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagCMSF92OhwCBxaA9ZxYmdxxFBQ3mtkKAStyh2bBo1JKvdRLD8MH4fM06yokilh54SJXYSx2P7G_vzN4y90LoseMiVR4taniil8YrAaE8ZCoWkUxMXtBv54yI6PBLvvsqJTbgeaZXkQ9tBKML11dS4l6WdGHF4REzsR0TMCvAS-jCIWS6zKxGJh9MuDn-xXUhIYz7shkMgSXmmTTxnPebU8HRKvPRsCOqGouwmU1MhBgbKybzv1Fz_-kff8UKlvMVujEAVXg6WdZtdMs0ddnUIXbm5y34TQaTegHESFDhyARmxqg2YnyO3tgF8Nyz7FbGRnAFAa4E88O_K8W_ABQgEHEgrDRb99lYhlu_g26r90R3DEAoI9o5V9ibbB7UB27vH0twxFIAOATgzxjbg1dWJASc6UTWw91nXwT7g2cGajLIiQjelre6xo-zgy6tDb4wB4WkRxJ2nSSwmkBqREi-TwpjIOogqE2NVmCRSJ0JIRDFK-Bp9YSXwPynfRGiCvJQqvM92mrYxDxn4vPBNgQjGpkKIuFQm9Q23PNXoYSgRzZiYqj7Xo0A6xemocz7qqE5VklOV5GOVzNh8m205KISclyH9267yzk3N2CGOSh6ek3d3MsJ87GzWuVvV5wi00hl7vr2N3QSt_RSNaXtMg0DbR-wfyv-kQSwtEbHJeMYeDAa-LVFIk2RBwB9d4OOfsWufXmf5h7eL94_ZdbrjeM_BLtvpVr15guiuU09d-_0Drq0_yQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Highly+efficient+soluble+expression+and+purification+of+recombinant+human+basic+fibroblast+growth+factor+%28hbFGF%29+by+fusion+with+a+new+collagen-like+protein+%28Scl2%29+in+Escherichia+coli&rft.jtitle=Preparative+biochemistry+%26+biotechnology&rft.au=Rahman%2C+Inamur&rft.au=Fang%2C+Linuo&rft.au=Wei%2C+Zhang&rft.au=Zheng%2C+Xiaodong&rft.date=2020-07-02&rft.issn=1532-2297&rft.volume=50&rft.issue=6+p.598-606&rft.spage=598&rft.epage=606&rft_id=info:doi/10.1080%2F10826068.2020.1721533&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1082-6068&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1082-6068&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1082-6068&client=summon